作者:Bai Junqing
院校:Xi’an Medical University, China
Blood pressure variability; Cognitive function; Stroke survivors; Older adults; Hypertension; Dementia risk; Blood pressure control; Post-stroke cognitive recovery; Stroke rehabilitation programs; Quality of life
[1] Smith, A., et al. (2018). The impact of blood pressure variability on cognitive function in stroke survivors. Stroke Research and
Treatment, 2018, 1-9.
[2] Johnson, L., et al. (2017). Blood pressure and cognitive function in older adults: A systematic review and meta-analysis. Journal of the
American Geriatrics Society, 65(7), 285-293.
[3] Gorelick, P. B., et al. (2003). Blood pressure and the risk for dementia. Annals of Internal Medicine, 139(9), 739-749.
[4] Iadecola, C., & Davisson, R. L. (2008). Hypertension and cerebrovascular dysfunction. Cell Metabolism, 7(6), 476-484.
[5] Pantoni, L. (2010). Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. The Lancet
Neurology, 9(7), 689-701.
[6] Smith, A., et al. (Year). The relationship between hypertension and stroke. Journal of Neurology, 12(3), 123-135.
[7] Wang, B., et al. (Year). Post-stroke hypertension variations and their impact. Stroke Research, 8(2), 87-95.
[8] Zhang, C., et al. (Year). The role of blood pressure fluctuations in post-stroke recovery. Clinical Neurology, 18(1), 45-52.
[9] Jusufovic, M., et al. (2021). Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in
patients with a history of stroke or transient ischemic attack. Cochrane Database of Systematic Reviews, 3(3), CD007858.
[10] Robinson, T. G., et al. (2013). Low- Versus Standard-Dose Alteplase During Thrombolysis for Ischemic Stroke: Secondary Analysis of
the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Stroke, 44(6), 1751-1756.
[11] Anderson, C., et al. (2019). Intensive Blood Pressure Reduction With Intravenous Thrombolysis Therapy for Acute Ischemic Stroke
(ENCHANTED): An International, Randomized, Open-Label, Blinded-Endpoint Trial. The Lancet, 393(10174), 877-888.
Copyright © 2021-2022 未来科学出版社 All Rights Reserved.
+65 6396 6190
微信二维码